Medication info
Esomeprazole Magnesium Trihydrate 20 mg Tablet

Esomeprazole Magnesium Trihydrate 20 mg Tablet

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
Sinphung Pharmaceutical Co., Ltd.
Appearance
Light pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2), 30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201403448 · Approved 2014.07.28 · Insurance code 648507220

Summary

Main use
Treatment and prevention of symptoms associated with reflux and Zollinger-Ellison syndrome, ulcers, Helicobacter pylori eradication, rebleeding, and NSAID use
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. Elderly patients: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Sinphung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of symptoms associated with reflux and Zollinger-Ellison syndrome, ulcers, Helicobacter pylori eradication, rebleeding, and NSAID use

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, particularly for long-term maintenance therapy to prevent the recurrence of erosive esophagitis. It also helps alleviate symptoms of gastroesophageal reflux disease without esophagitis. It is effective in treating and preventing recurrence of duodenal ulcers or peptic ulcers in conjunction with antibiotics for the eradication of Helicobacter pylori. Additionally, it is used to treat symptoms (pain, discomfort, burning sensation) of upper gastrointestinal tract that may occur with the intake of non-steroidal anti-inflammatory drugs, and for the treatment and prevention of gastric ulcers or duodenal ulcers caused by them. It is also appropriate for treating Zollinger-Ellison syndrome and maintaining therapy to prevent gastric or duodenal ulcer rebleeding. Therefore, this drug is widely used in the treatment and prevention of various gastrointestinal-associated diseases.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. Elderly patients: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Patients with known allergies or a history of hypersensitivity to this medication or its ingredients should not use it. Additionally, caution is needed as allergic reactions may occur when used in conjunction with certain antibiotics. Patients with specific heart conditions or those who are breastfeeding should also refrain from taking this medication. This medication contains specific coloring agents, so patients with a history of allergies to these components should use it with care. Various adverse reactions may occur while taking this medication. For example, decreased blood cell count, allergic reactions, electrolyte imbalance, neurological symptoms, digestive issues, liver function abnormalities, skin rashes, etc. have been reported. Rarely, serious skin conditions or muscle-related issues may arise; if symptoms appear, consult a physician immediately. This medication can mask symptoms of malignant tumors, so it is essential to consult with a specialist if serious gastrointestinal symptoms are present. Regular check-ups are necessary for long-term use, and it is important to consult with a physician if there are changes in symptoms. This medication suppresses gastric acid secretion and may cause bacterial overgrowth in the stomach, slightly increasing the risk of infections such as diarrhea. Furthermore, long-term use may increase the risk of fractures, so careful monitoring is required in patients at risk for osteoporosis. This medication may interact with other drugs, so it is crucial to inform healthcare providers about any other medications being taken. Special caution is needed when used in conjunction with anticoagulants, antiviral agents, antibiotics, and anticonvulsants. Safety data on this medication during pregnancy is limited, and it should be used cautiously under a doctor’s supervision during pregnancy. It is recommended to avoid using it during breastfeeding due to unknown transmission into breast milk. In cases of overdose, there is no specific antidote; treatment should follow symptom management and standard care, as it is not removed by dialysis. This medication should be kept out of reach of children, and care should be taken not to transfer it to other containers, as this may affect its quality.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, alopecia, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, elevated ALT, elevated AST, diabetes, hyperuricemia, elevated ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, spasms, fibromyalgia syndrome, hernia, polymyalgia rheumatica, anorexia, apathy, increased appetite, confusion, worsening depression, muscle hypertonia, sensory reduction, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorder, tremor, visual field loss, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, dysosmia, loss of taste, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air and moisture from entering. It is best to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Light pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2), 30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.